Chinese ADC Developers Catch Up with Global Players In Advancing Key Payloads
Multiple Active Players
Executive Summary
Chinese pharma firms led by Kelun are moving fast to develop the next-generation of cytotoxic "warheads," a key component of antibody-drug conjugates, disclosed company executives at conference in Suzhou.
You may also be interested in...
BeiGene Joins Antibody-Drug Conjugate Stampede With DualityBio Deal
The deal, focused on a preclinical candidate and worth more than $1bn, follows DualityBio’s licensing agreement in April with BioNTech, amid growing interest among drug makers in ADCs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: 10 big upcoming US biosimilar launches; Kisqali strikes gold in early adjuvant breast cancer; Zolgensma shows the promise and limitations of gene therapy; Chinese biotechs advancing multiple ADCs; and Scrip Asks about diversity, equity and inclusion in pharma.
China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.